Covenant Research and Clinics (United States)

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

Stephen A. Harrison, Peter Ruane, B. Freilich et al. · Nature Medicine · 2021 · 320 citations

Hepatology, Liver Physiology, Pharmacology +4

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

Rohit Loomba, Mazen Noureddin, Kris V. Kowdley et al. · Hepatology · 2020 · 260 citations

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis

Stephen A. Harrison, Guy Neff, Cynthia D. Guy et al. · Gastroenterology · 2020 · 257 citations · Full text

Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial

˜The œLancet. Gastroenterology & hepatology · 2022 · 124 citations

Hepatology, Nonalcoholic Fatty Liver Disease, Pharmacology +5

A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes

Stephen A. Harrison, Nadege Gunn, Guy Neff et al. · Nature Communications · 2021 · 111 citations · Full text